.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Precision oncology is rapidly transforming cancer therapy by tailoring treatments to individual genetic profiles. Currently, the adoption of advanced precision oncology testing is expanding beyond metropolitan hospitals into smaller cities across India. Furthermore, Bengaluru-based startup 4baseCare recently secured an additional Rs 38 crore in a top-up round led by growX Ventures and Infosys. Consequently, its total Series B funding has reached Rs 128 crore. The company plans to utilize this capital to scale its artificial intelligence platform and expand its global laboratory network.
Historically, genomic testing datasets and clinical trials have focused heavily on Caucasian populations in the United States and Europe. This geographic concentration often limits treatment insights for patients in emerging markets. Consequently, 4baseCare aims to build solutions specifically for underrepresented populations in regions such as India, the Middle East, Southeast Asia, and Latin America. Additionally, the startup operates active laboratories in India, Dubai, Nepal, and the Philippines. Indeed, the organization plans to expand into ten additional countries over the next 18 months.
In addition to international expansion, 4baseCare is actively decentralizing genomic testing infrastructure across India. Typically, clinics send all patient samples to centralized facilities in major metros like Bengaluru. Instead of relying on this model, the startup is setting up in-hospital genomics labs. Recently, the company established strategic partnerships with major institutions including Max Healthcare, AIIMS Jammu, and Shankara Hospital. This decentralized approach brings advanced technology closer to clinicians and patients. Consequently, it significantly reduces turnaround times, enhances local research collaboration, and makes advanced cancer testing far more accessible.
Technology plays a critical role in modern precision oncology testing. For instance, 4baseCare's proprietary platform, OncoTwin, utilizes multimodal datasets to create \"digital twins\" of cancer patients. Specifically, it combines genomic, pathology, radiology, and clinical records to map individual treatment journeys. By comparing these digital profiles, the platform provides clinicians with real-world evidence of therapies that worked for similar patients. Ultimately, this clinical decision support tool helps oncologists select highly personalized remedies like targeted therapies and immunotherapies, which are vital for advanced-stage cancer cases.
Q1: What is OncoTwin?
OncoTwin is an AI-powered clinical decision support platform developed by 4baseCare. It creates digital twins of cancer patients by analyzing multimodal datasets, helping oncologists find real-world evidence of successful treatments for similar patients.
Q2: Why is decentralizing genomic testing important?
Decentralizing testing via in-hospital labs reduces sample shipping times, improves diagnostic turnaround times, and enhances research collaboration, bringing advanced cancer diagnostics closer to patients in tier 2 and tier 3 cities.
Q3: How does precision oncology benefit cancer patients?
Precision oncology uses genomic testing to identify specific molecular changes in a tumor. Consequently, doctors can prescribe targeted therapies and immunotherapies instead of generic chemotherapy, resulting in more effective, personalized treatment.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Precision oncology startup 4baseCare raises Rs 128 crore, backed by Infosys and growX Ventures, to scale its AI platform OncoTwin and expand its genomics lab network globally. Learn how this funding will decentralize cancer testing and improve personalized oncology care in India and beyond.
last month
A parliamentary panel has urged the FSSAI to finalise front-of-pack nutrition labelling regulations without further delay. The committee stressed that simple, color-coded indicators for sugar and clear warning labels are vital to combat dietary non-communicable diseases and guide informed consumer choices.
3 days back
A comprehensive analysis of the NFHS-5 data regarding postpartum anemia in India, exploring the prevalence, severity, and the socioeconomic and regional factors contributing to this public health challenge for clinicians seeking to improve maternal health outcomes.
Last week
A study in Greece reveals that 46-80% of heatwave deaths are linked to climate change. This analysis explores the implications for public health and clinical practice, particularly for elderly and vulnerable populations facing rising global temperatures in regions like India.
2 weeks back
Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
last month
A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
3 days back
